Ampio Pharmaceuticals Breaks Ground on Construction of Ampion™ Manufacturing Facility

 Ampio Pharmaceuticals Breaks Ground on Construction of Ampion™ Manufacturing
                                   Facility

Expected to create approximately 40 new jobs over next two years

PR Newswire

GREENWOOD VILLAGE, Colo., Jan. 15, 2014

GREENWOOD VILLAGE, Colo., Jan. 15, 2014 /PRNewswire/ --Ampio Pharmaceuticals,
Inc. (NYSE MKT: AMPE) held a groundbreaking ceremony on Friday, January 10th
to announce the start of construction of its new state-of-the-art
manufacturing facility for its lead drug candidate, Ampion™, for the treatment
of patients afflicted with osteoarthritis of the knee. Located in the Denver
Metro area, the facility is expected to be ready for production of Ampion™ in
the summer of 2014 and should generate approximately 40 new jobs in the next
two years.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

"Bioscience continues to be a key industry in Colorado and an important part
of our advanced industry growth," said Ken Lund, Executive Director of the
Colorado Office of Economic Development and International Trade. "We are
pleased that Ampio Pharmaceuticals has chosen to increase its employee base
and capital investment in Colorado."

April Giles, President and CEO, Colorado BioScience Association remarked "We
congratulate Ampio Pharmaceuticals on their decision to locate their new
manufacturing facility in the Denver Tech Center.Ampio Pharmaceutical's
decision to grow their company in Colorado and to focus on innovative methods
of treating patient's with debilitating medical conditions has served the
company and the community well."

"The construction of this manufacturing facility will accomplish a major
milestone for the commercialization of Ampio's lead drug," said Michael
Macaluso, Chairman and CEO of Ampio. "We are excited about the prospect of
bringing a safe and effective medicine to patients whose quality of life have
suffered due to osteoarthritis of the knee. Having announced positive trial
results for the initial pivotal trial (SPRING STUDY) late last year, and the
start of the final pivotal trial (STEP STUDY) this week, we look forward to
reaching commercial-scale production of Ampion™ that would follow FDA
clearance of the drug. The facility will have an annual production capacity of
approximately ten million doses of Ampion™. More than 50% of the source
material, human serum albumin or HSA, required to meet this capacity has
already been secured through a long-term, non-exclusive, supply agreement as
previously announced."

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company
primarily focused on the development of therapies to treat prevalent
inflammatory conditions for which there are limited treatment options. We are
developing compounds that decrease inflammation by (i) inhibiting specific
pro-inflammatory compounds by affecting specific pathways at the protein
expression and at the transcription level; (ii) activating specific
phosphatase or depletion of the available phosphate needed for the
inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements

Ampio's statements in this press release that are not historical fact and that
relate to future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such as
"believe," "expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's expectations
with respect to the completion, timing and size of the registered direct
offering, as well as risks associated with clinical trials, expected results,
regulatory approvals, and changes in business conditions and similar events.
The risks and uncertainties involved include those detailed from time to time
in Ampio's filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Ampio undertakes no obligation to revise or update
these forward-looking statements, whether as a result of new information,
future events or otherwise.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com



SOURCE Ampio Pharmaceuticals, Inc.

Website: http://www.ampiopharma.com